Description

Argatroban is a synthetic direct thrombin inhibitor widely studied in laboratory research for models of thrombosis, heparin?induced thrombocytopenia (HIT), and acute ischemic stroke. It reversibly binds to thrombin’s active site, blocking fibrin formation and clot stabilization.

Each vial provides 10?mg in 2?ml sterile solution, produced by Borui Pharmaceutical (Suzhou) Co., Ltd., and approved by the NMPA under H20223094, with product code 86980081000116, barcode 6973398250101.

?? This product is strictly for laboratory research use only and not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Argatroban binds directly to thrombin (Factor IIa), preventing fibrin clot formation. It is used in lab studies focused on:

• Heparin?induced thrombocytopenia (HIT)

• Acute ischemic stroke

• Venous thromboembolism prevention

• Coagulation pharmacology and assay development

Side Effects (Observed in Research Models)

At research?grade dosing, argatroban may cause:

• Bleeding risks, including internal hemorrhage or hypotension

• Injection site irritation in animal studies

Safety & Handling

For research use only. Use PPE: gloves, lab coat, goggles. Dispose of per institutional biohazard protocols. Store away from direct light at room temperature.

Research Use Disclaimer

This product is intended solely for laboratory research use and is not approved for clinical, diagnostic, or veterinary use. Misuse may cause serious health and regulatory risks. Always handle under institutional safety guidelines.